Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07 2022 - 8:00AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease, today
announced preclinical data from the company’s novel GADLEN platform
at the 2022 SITC Annual Meeting.
“The data presented from these two compounds demonstrate the
broad utility of the GADLEN platform to direct gamma delta T cells
to kill target cells expressing an antigen (or antigens) of our
choosing,” said Taylor Schreiber, M.D., Ph.D., Chief Executive
Officer of Shattuck. “B7-H3 is an antigen that is broadly expressed
by many solid tumors, with limited expression in normal tissues. In
our preclinical models, our B7-H3 GADLEN directed human gamma delta
T cells to selectively kill B7-H3 expressing human tumor cells,
including those that expressed very low density of the B7-H3
antigen. Similarly, in our preclinical models, our CD20 GADLEN
directed human gamma delta T cells to selectively kill both CD20
expressing tumor cells, and also CD20 expressing healthy B cells.
The latter activity with the CD20 GADLEN may have distinct value in
antibody-mediated autoimmunity, where non-Ig, non-CD3 based cell
depletion strategies could have a unique therapeutic window.”
Details of the presentation are as follows:
Abstract title: Antigen targeted butyrophilin
heterodimer-based bispecific engagers induce T cell-mediated
anti-tumor activity
Shattuck presented preclinical data highlighting the potential
of GADLENs to direct Vγ9δ2+ T cells to kill tumor cells. The
bispecific GADLENs, which contain heterodimeric BTN2A1 and BTN3A1
extracellular domains fused via inert Fc linkers to scFv domains,
targeting CD20 or B7-H3 antigens, demonstrated cytotoxic ability in
coculture with Vγ9δ2+ T cells. CD20-directed GADLENs enhanced the
specific killing of lymphoma cells and healthy B cells that express
the antigen, while B7H3-directed GADLEN increased the killing of
B7-H3 expressing tumor cells. These studies shed light on the
modularity of the GADLEN platform and the tumor cell markers which
are important for the therapeutic activity of gamma delta T
cell-based engager therapies.
Further information about the Society for Immunotherapy of
Cancer Meeting can be found at:
https://www.sitcancer.org/2022/home. The poster will be
available on the Posters section of the Company’s website
shortly after the event.
About Shattuck Labs, Inc.Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease. Compounds derived from Shattuck’s proprietary
Agonist Redirected Checkpoint, ARC®, platform simultaneously
inhibit checkpoint molecules and activate costimulatory molecules
with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L)
program, which is designed to block the CD47 immune checkpoint and
simultaneously agonize the CD40 pathway, is being evaluated in
multiple Phase 1 trials. A second product candidate, SL-279252
(PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid
tumors or lymphomas. Additionally, the company is advancing a
proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is
designed to bridge gamma delta T cells to tumor antigens for the
treatment of patients with cancer. Shattuck has offices in both
Austin, Texas and Durham, North Carolina. For more information,
please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its
website as a means of disclosing material non-public information
and for complying with disclosure obligations under Regulation
FD.
Investor Contact:Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024